Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis 1 1 Work was performed at Stanford University School of Medicine, Department of Medicine, Division of Pulmonary and Critical Care Medicine; the Graduate School of Business of Stanford University; and Sunnybrook and Women’s College Health Sciences Centre, University of Toronto. Subsequent to completion of this economic evaluation, Robert Fowler, has agreed to participate in further study of the effects of rhAPC for patients with early stage severe sepsis, through a multicenter clinical trial sponsored by Eli Lilly.
Titel:
Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis 1 1 Work was performed at Stanford University School of Medicine, Department of Medicine, Division of Pulmonary and Critical Care Medicine; the Graduate School of Business of Stanford University; and Sunnybrook and Women’s College Health Sciences Centre, University of Toronto. Subsequent to completion of this economic evaluation, Robert Fowler, has agreed to participate in further study of the effects of rhAPC for patients with early stage severe sepsis, through a multicenter clinical trial sponsored by Eli Lilly.
Auteur:
Fowler, Robert A Hill-Popper, Marya Stasinos, John Petrou, Constantia Sanders, Gillian D Garber, Alan M